DE60136169D1 - Immunregulierer - Google Patents
ImmunreguliererInfo
- Publication number
- DE60136169D1 DE60136169D1 DE60136169T DE60136169T DE60136169D1 DE 60136169 D1 DE60136169 D1 DE 60136169D1 DE 60136169 T DE60136169 T DE 60136169T DE 60136169 T DE60136169 T DE 60136169T DE 60136169 D1 DE60136169 D1 DE 60136169D1
- Authority
- DE
- Germany
- Prior art keywords
- immune
- adjuster
- nmpf
- disease
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00201139A EP1138692A1 (de) | 2000-03-29 | 2000-03-29 | Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren |
PCT/NL2001/000259 WO2001072831A2 (en) | 2000-03-29 | 2001-03-29 | Immunoregulator |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60136169D1 true DE60136169D1 (de) | 2008-11-27 |
Family
ID=8171269
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60136577T Expired - Lifetime DE60136577D1 (de) | 2000-03-29 | 2001-03-29 | Fragmente des menschlichen Choriogonadotropin (hcg) als Immunregulator |
DE60136169T Expired - Lifetime DE60136169D1 (de) | 2000-03-29 | 2001-03-29 | Immunregulierer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60136577T Expired - Lifetime DE60136577D1 (de) | 2000-03-29 | 2001-03-29 | Fragmente des menschlichen Choriogonadotropin (hcg) als Immunregulator |
Country Status (18)
Country | Link |
---|---|
US (2) | US7365155B2 (de) |
EP (3) | EP1138692A1 (de) |
JP (1) | JP5172064B2 (de) |
KR (1) | KR100800876B1 (de) |
AT (2) | ATE411340T1 (de) |
AU (1) | AU781632B2 (de) |
CA (1) | CA2407046C (de) |
CY (2) | CY1108706T1 (de) |
DE (2) | DE60136577D1 (de) |
DK (2) | DK1887016T3 (de) |
ES (2) | ES2317620T3 (de) |
HK (1) | HK1052360B (de) |
IL (2) | IL151945A0 (de) |
NZ (1) | NZ521703A (de) |
PT (2) | PT1887016E (de) |
SG (1) | SG127739A1 (de) |
SI (2) | SI1887016T1 (de) |
WO (1) | WO2001072831A2 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
US8680059B2 (en) | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
EP1138692A1 (de) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren |
US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
US6844315B2 (en) | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
EP1300418A1 (de) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Genregulation durch Oligopeptide |
US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
EP1466611A1 (de) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Verwendung von HCG Peptidderivate zur Behandlung von iatrogene Krankheiten |
KR101184833B1 (ko) * | 2003-04-08 | 2012-09-20 | 바이오템프트, 비.브이. | Hcg 절편들을 포함하는 점막 및 경구 투여용 조성물 |
US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
EP1466613A1 (de) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | HCG-Fragmente enthaltene Zusammensetzungen zur mukosalen und oralen Anwendung |
EP1466612A1 (de) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Behandlung von Entzündung und Sepsis mit hCG-Peptidderivate |
US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
WO2006090874A1 (ja) * | 2005-02-25 | 2006-08-31 | Nihon University | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
WO2007004869A2 (en) * | 2005-07-05 | 2007-01-11 | Biotempt B.V. | Treatment of tumors |
DE102005054454A1 (de) * | 2005-11-09 | 2007-06-28 | Universität Duisburg-Essen | Verwendung von Choriongonadotropin als Immunsuppressivum |
EP1864692A1 (de) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Verwendung von peptiden zum Schutz von Strahlenschäden |
SG178780A1 (en) * | 2007-02-12 | 2012-03-29 | Biotempt Bv | Treatment of trauma-hemorrhage with short oligopeptides |
US20080217002A1 (en) * | 2007-03-07 | 2008-09-11 | Floyd Randolph Simonds | Sand control screen having a micro-perforated filtration layer |
WO2009085180A1 (en) * | 2007-12-20 | 2009-07-09 | The Feinstein Institute For Medical Research | Treatment of sepsis and inhibition of mif by d-t4 |
EP2109054A1 (de) | 2008-04-09 | 2009-10-14 | Biotempt B.V. | Verfahren zur Identifizierung biologisch aktiver Peptide und Vorhersage ihrer Funktion |
EP2490021A1 (de) | 2011-02-18 | 2012-08-22 | Biotempt B.V. | Modulatoren von PRR- und GPCR-Signalisierung |
CN104415162B (zh) * | 2013-08-21 | 2018-05-15 | 常州市肿瘤医院 | 治疗放化疗后白细胞减少症的中药组合物及其制备方法 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4571336A (en) | 1983-08-25 | 1986-02-18 | Endorphin, Inc. | Immune stimulation |
US4977244A (en) | 1985-06-27 | 1990-12-11 | The United States Of America As Represented By The Department Of Health And Human Services | Uromodulin and a process of purifying it |
US4855285A (en) * | 1985-12-04 | 1989-08-08 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
JPH0680015B2 (ja) | 1986-05-12 | 1994-10-12 | ザ ウエルカム ファウンデーション リミテッド | 医薬組成物 |
US5055447A (en) | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
US5308834A (en) | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US6051596A (en) | 1990-08-10 | 2000-04-18 | Anormed, Inc. | Immunosuppressive compositions |
US5958413A (en) | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
JPH06508029A (ja) | 1991-05-17 | 1994-09-14 | カイロン コーポレイション | NF−↓kB転写活性化物質のインヒビター及びその使用 |
DE4138621A1 (de) | 1991-11-25 | 1993-06-17 | Boehringer Ingelheim Int | Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg |
PT633929E (pt) * | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
ES2103854T3 (es) | 1992-05-30 | 1997-10-01 | Sikiric Predrag | Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia. |
US5436270A (en) | 1993-04-07 | 1995-07-25 | National Science Council | Method for protecting against endotoxin-induced shock |
US5380668A (en) | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
US5837478A (en) | 1993-12-23 | 1998-11-17 | Icos Corporation | Method of identifying modulators of binding between and VCAM-1 |
US5677275A (en) | 1994-08-05 | 1997-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
US5700781A (en) | 1994-10-04 | 1997-12-23 | Harris; Pamela Jo | Method for treating Kaposi's sarcoma and HIV infections |
US5851997A (en) | 1994-10-04 | 1998-12-22 | Harris; Pamela Jo | Use of human chorionic gonadotropin as an immune-potentiating antiviral agent |
SE520730C2 (sv) | 1995-01-20 | 2003-08-19 | Eskil Elmer | Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel |
WO1996032412A1 (fr) | 1995-04-13 | 1996-10-17 | Chugai Seiyaku Kabushiki Kaisha | PEPTIDE SUPPRIMANT LA PHOSPHORYLATION IxB$g(a) |
WO1996033218A1 (en) | 1995-04-21 | 1996-10-24 | Allelix Biopharmaceuticals Inc. | Anti-haemorrhagic peptides |
US6361992B1 (en) | 1996-05-08 | 2002-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Thyroid stimulating hormone superagonists |
US5968513A (en) * | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
AU3587797A (en) * | 1996-06-24 | 1998-01-14 | University Of Maryland Biotechnology Institute | Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin |
US5997871A (en) * | 1996-06-24 | 1999-12-07 | University Of Maryland Biotechnology Insitute | Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
US6150500A (en) | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
GB9617021D0 (en) | 1996-08-13 | 1996-09-25 | Salpep Biotechnology Inc | Novel peptides for treatment of inflammation and shock |
EP1005354A4 (de) | 1997-02-07 | 2002-05-15 | Univ Jefferson | Peptidmimetika der zytokinrezeptor gammakette |
EP0979096B1 (de) | 1997-02-15 | 2003-05-14 | Millennium Pharmaceuticals, Inc. | Behandlung von infarkten durch inhibierung von nf-kappab |
US5801193A (en) | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
DE19735587B4 (de) | 1997-08-16 | 2012-03-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens |
HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
US6652860B1 (en) | 1997-12-12 | 2003-11-25 | University Of Western Ontario | Peptide, apoEp 1.B, compositions and uses thereof |
US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
NZ508438A (en) * | 1998-05-20 | 2004-03-26 | Univ Erasmus | Immunoregulator |
US6844315B2 (en) | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
EP1138692A1 (de) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren |
US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
RU2139085C1 (ru) | 1998-06-23 | 1999-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Средство, стимулирующее репаративные процессы, и способ его применения |
WO2000017348A1 (en) | 1998-09-17 | 2000-03-30 | Hopital Sainte-Justine | G protein-coupled receptor agonists or antagonists |
IL143219A0 (en) | 1998-11-20 | 2002-04-21 | Mount Sinai Hospital Corp | Peptides that modulate the interaction of b class ephrins and pdz domains |
US6507788B1 (en) | 1999-02-25 | 2003-01-14 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function |
WO2000053621A2 (en) | 1999-03-09 | 2000-09-14 | Jeffrey Lynn Haddox | Synthetic complementary peptides and ophthalmologic uses thereof |
US20030148955A1 (en) | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
RU2157233C1 (ru) | 1999-05-11 | 2000-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения |
US7994278B1 (en) | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
CA2378480A1 (en) | 1999-08-09 | 2001-02-15 | Tripep Ab | Pharmaceutical compositions containing tripeptides |
US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
BR0014742A (pt) | 1999-10-15 | 2002-08-27 | Histatek Llc | Método para a inibição de uma resposta pró-inflamatória de uma célula mononuclear e célula polimorfonuclear de sangue periférico humano, ou uma célula de tecido fixado, quando contactada com um agente pró-inflamatório, complexo de receptor, e, método para a identificação de um agente de modificação de via de sinal de proteìna g quinase |
RU2155063C1 (ru) | 1999-10-20 | 2000-08-27 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения |
WO2001036454A1 (en) | 1999-11-18 | 2001-05-25 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
DE60110396T2 (de) | 2000-01-14 | 2006-01-19 | Larson, Richard S., Albuquerque | Peptidische inhibitoren der lfa-1/icam-1 interaktion |
WO2001059084A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
AU2001245537A1 (en) | 2000-03-10 | 2001-09-24 | Monsanto Company | Anti-hypertensive peptides |
EP1300418A1 (de) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Genregulation durch Oligopeptide |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US6783757B2 (en) | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
US6586403B1 (en) | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
US20020155106A1 (en) | 2000-12-01 | 2002-10-24 | Hammond David J. | Method of identifying a ligand for a target molecule |
WO2002085117A1 (en) | 2001-04-24 | 2002-10-31 | Eisai Co., Ltd. | Methods and compositions for preventing and treating septic shock and endotoxemia |
US20030220259A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
US20030224995A1 (en) | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20030220260A1 (en) | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
US20030220257A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US20040013661A1 (en) | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
US20030220261A1 (en) | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US7135286B2 (en) | 2002-03-26 | 2006-11-14 | Perlegen Sciences, Inc. | Pharmaceutical and diagnostic business systems and methods |
US7217507B2 (en) | 2002-04-15 | 2007-05-15 | The American National Red Cross | Method for detecting ligands and targets in a mixture |
US7517529B2 (en) | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
WO2007004869A2 (en) | 2005-07-05 | 2007-01-11 | Biotempt B.V. | Treatment of tumors |
EP1864692A1 (de) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Verwendung von peptiden zum Schutz von Strahlenschäden |
-
2000
- 2000-03-29 EP EP00201139A patent/EP1138692A1/de active Pending
-
2001
- 2001-03-29 SI SI200130895T patent/SI1887016T1/sl unknown
- 2001-03-29 DK DK07108784T patent/DK1887016T3/da active
- 2001-03-29 PT PT07108784T patent/PT1887016E/pt unknown
- 2001-03-29 CA CA2407046A patent/CA2407046C/en not_active Expired - Lifetime
- 2001-03-29 AT AT01922133T patent/ATE411340T1/de active
- 2001-03-29 ES ES07108784T patent/ES2317620T3/es not_active Expired - Lifetime
- 2001-03-29 DK DK01922133T patent/DK1272515T3/da active
- 2001-03-29 SI SI200130892T patent/SI1272515T1/sl unknown
- 2001-03-29 NZ NZ521703A patent/NZ521703A/en not_active IP Right Cessation
- 2001-03-29 AU AU48913/01A patent/AU781632B2/en not_active Expired
- 2001-03-29 EP EP01922133A patent/EP1272515B1/de not_active Expired - Lifetime
- 2001-03-29 SG SG200405399A patent/SG127739A1/en unknown
- 2001-03-29 WO PCT/NL2001/000259 patent/WO2001072831A2/en active IP Right Grant
- 2001-03-29 DE DE60136577T patent/DE60136577D1/de not_active Expired - Lifetime
- 2001-03-29 DE DE60136169T patent/DE60136169D1/de not_active Expired - Lifetime
- 2001-03-29 IL IL15194501A patent/IL151945A0/xx unknown
- 2001-03-29 ES ES01922133T patent/ES2315278T3/es not_active Expired - Lifetime
- 2001-03-29 PT PT01922133T patent/PT1272515E/pt unknown
- 2001-03-29 KR KR1020027012952A patent/KR100800876B1/ko active IP Right Grant
- 2001-03-29 AT AT07108784T patent/ATE414104T1/de active
- 2001-03-29 EP EP07108784A patent/EP1887016B1/de not_active Expired - Lifetime
- 2001-03-29 JP JP2001571762A patent/JP5172064B2/ja not_active Expired - Fee Related
-
2002
- 2002-09-26 IL IL151945A patent/IL151945A/en active IP Right Grant
- 2002-09-30 US US10/262,522 patent/US7365155B2/en not_active Ceased
-
2003
- 2003-06-27 HK HK03104599.4A patent/HK1052360B/zh not_active IP Right Cessation
-
2009
- 2009-01-13 CY CY20091100022T patent/CY1108706T1/el unknown
- 2009-02-03 CY CY20091100124T patent/CY1110259T1/el unknown
-
2011
- 2011-03-17 US US13/065,318 patent/USRE43140E1/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60136169D1 (de) | Immunregulierer | |
ATE249835T1 (de) | Immunoregulator | |
HUP0301789A2 (hu) | Rekombináns anti CD40 ellenanyagok és használatuk | |
CY1112425T1 (el) | Αντισωματα αντι-ngf για την θεραπευτικη αγωγη διαφορων διαταραχων | |
DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
DE60126923D1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
CY1105349T1 (el) | Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec | |
DK1539166T3 (da) | Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme | |
MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
ATE556713T1 (de) | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer | |
IS6667A (is) | Aðferðir til að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4 sameind | |
WO2003030934A3 (en) | Cpg formulations and related methods | |
DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
BR0201862A (pt) | Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos | |
PT1057828E (pt) | Suspensoes de trovafloxacina para administracao oral | |
DK1453798T3 (da) | (20S)-1alfa-hydroxy-2-methylen-19-nor-bishomopregnacalciferol og anvendelser deraf | |
PT1187612E (pt) | Utilizacao do riluzole para o tratamento da esclerose multipla | |
DE50207168D1 (de) | Kombinationspräparat zur Therapie von immunologischen Erkrankungen | |
CY1106552T1 (el) | Ενωσεις ισοχρωμανιου για την θεραπεια ανωμαλιων του κνς | |
DK1299350T3 (da) | Substituerede benzamider til styrket immunforsvar og behandling af kræft, infektioner og manio-depressive sygdomme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |